NEW YORK, Jan. 27 (GenomeWeb News) - Alnylam Pharmaceuticals, through its German affiliate, Ribopharma, has granted a license to its RNAi patent to Ribopharma, the company said today.
The patent covers the use of short double-stranded RNAs for RNA interference. RNAx, based in Berlin, will pay an initial and annual licensing fees, as well as royalties on services it provides using the technology.
Earlier this month, Alnylam, based in Cambridge, Mass., licensed the patent to Invitrogen, Cell Signaling Technology, and Cenix Bioscience.